Find a Doctor or Practice Location

Evaluation and medical treatment of patients with obesity and its complications. Novel therapies for treating obesity. Pre-and post bariatric surgery care. Medical treatment of Diabetes Mellitus. Continuos glucose monitors. Continuous insulin infusion devices (insulin pumps). Hypoglycemia after baratric surgery. Insulinoma.

Medical School: Sechenov I Moscow Medical Institute
Residency: Sechenov I Moscow Medical Institute
Residency: Advocate Lutheran General Hospital
Fellowship: Barnes-Jewish Hospital - Washington University, St. Louis

American Association of Clinical Endocrinologists, National American Diabetes Association, National The Endocrine Society, National The Obesity Society, National

Hospital Privileges:

• Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
• Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Description of Research Expertise:

Diabetes and obesity clinical trials.

Selected Publications:

Amaryah Yaeger, Nancy Cash, Tara Parham, David Frankel, Rajat Deo, Robert Schaller, Pasquale Santangeli, Saman Nazarian, Gregory Supple, Jeffrey Arkles, Michael Riley, Fermin Garcia, David Lin, Andrew Epstein, David Callans, Francis Marchlinski, Daniel Kolansky, Jorge Mora, Anastassia Amaro, Richard Schwab, Allan Pack, and Sanjay Dixit.: A Nurse-Led Limited Risk Factor Modification Program to Address Obesity and Obstructive Sleep Apnea in Atrial Fibrillation Patients Journal of the American Heart Association. 2018;7:e010414 : 2018.

Amaryah Yaeger, Nancy R Cash, Tara Parham, Anastassia Amaro, Rajat Deo, David S Frankel, Andrew E Epstein, Pasquale Santangeli, Michael Riley, Saman Nazarian, David Lin, Fermin C Garcia, Robert Schaller, Jeffrey Arkles, Gregory Supple, Ramanan Kumareswaran, David J Callans, Francis E Marchlinski, and Sanjay Dixit: Efficacy of a Nurse-Led Risk Factor Modification Program in Achieving Weight Loss in Obese Atrial Fibrillation Patients Circulation: Cardiovascular Quality and Outcomes. 2018;11:A146 : 2018.

Crawford AR, Alamuddin N, Amaro A.: Cardiometabolic Effects of Anti-Obesity Pharmacotherapy Curr Atheroscler Rep. 2018:18. doi: 10.1007/s11883-018-0719-9. Review. : 2018.

Amy von Sydow Green, Ashley Bush, Anastassia Amaro and Megin Adams Myers: Group weight management classes can produce effective weight loss in a medical weight loss center Poster Presentation at the Obesity Week, Nashville, November 2018. : 2018.

ANDREW CRAWFORD, LAURA G. COONEY, NICOLE JOCHYM, ANUJA DOKRAS and ANASTASSIA AMARO: Insulin Resistance and Weight Loss in Obese Women with Polycystic Ovary Syndrome Treated with Liraglutide—Single Institution Experience Diabetes 2018 Jul; 67(Supplement 1): -. : 2018.

Thompson C., Abu Dayyeh B., Kushner R., Sullivan S., Schorr A, Amaro A, Apovian C, Fullum T, Zarrinpar A, Jensen M, Stein A, Edmundowicz S, Kahaleh M, Ryou M, Bohning J.M., Ginsberg G., Huang C, Tran D., Martin J., Jaffe D., Farraye F., Ho S., Kumar N., Harakal D., Young M., Thomas C., Shukla A., Ryan M., Haas M., Goldsmith H., McCrea J., Aronne L.: Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial American Journal of Gastroenterology 112 (3): 447-457,2017.

Chantal Lewis MB,BS; Julia Kharlip MD; Anastassia Amaro MD : Use of Liraglutide in Childhood Onset Non-Craniopharyngioma Related Hypothalamic Obesity. Poster presentation at the Obesity Society annual meeting, Los Angeles, CA in November 2015. : 2015.

Vetter ML, Amaro A, Volger S.: Nutritional management of type 2 diabetes mellitus and obesity and pharmacologic therapies to facilitate weight loss. Postgrad Med. 2014 Jan;126(1):139-52. : 2014.

Amaro A., Fabbrini E., Kars M., Yue P, Schonfeld G., Klein S.: Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia Gastroenterology 139 (1): 149-153,2010.

Amaro A., Kars M., Fabbrini E., Mohammed B., Yue P, Schonfeld G., Klein S.: Increased intrahepatic triglyceride content does not cause insulin resistance in subjects with familial hypobetalipoproteinemia The Obesity Society Annual Scientific Meeting, Washington, DC : 2009.